Zeneca sues US rival over `false' drug claims
Saturday 27 February 1999
In a lawsuit filed in a New York court, the British group alleged that the US drug giant "systematically and deliberately attempted to mislead doctors" on the benefits of Evista, an osteoporosis drug.
According to Zeneca, Lilly's sales representatives told physicians that the drug helped to reduce the risk of breast cancer, even though it had only been approved as a treatment for osteoporosis - a bone-thinning disease which affects middle-aged women.
The UK company is the maker of Nolvadex, the leading product for the treatment of breast cancer, and one of Zeneca's best selling drugs. Last year Nolvadex sales totalled $369m in the US and around $500m worldwide. The drug is used by around 400,000 US patients and last year received approval to be used to prevent the disease in high-risk women.
The lawsuit said that Lilly's false claims prompted a number of doctors to prescribe Evista for breast cancer, leading to a drop in the sales of Nolvadex.
According to a Zeneca survey of over 500 doctors, one in three physicians were led to believe that Evista could be used as an alternative to Nolvadex. .Zeneca, which is merging with its Swedish rival Astra, claimed that Lilly's campaign created "serious risk to public health" as more and more women are using Evista instead of Nolvadex. The British company is seeking undisclosed damages and wants Lilly to pay for an advertising campaign to deny the Evista cancer claims.
A spokesman for Lilly yesterday denied Zeneca's allegations: "We don't feel there is anything inappropriate in our promotion."
- 1 David Cameron refers to 83-year-old Labour MP Dennis Skinner as 'Jurassic Park'
- 2 Tunisia hotel attack: Locals form 'human shield' to protect hotel from gunman Seifeddine Rezgui
- 3 Optical illusion turns blue demon into brunette
- 4 German ethics council calls for incest between siblings to be legalised by Government
- 5 Saudi Prince Alwaleed bin Talal will donate entire $32bn fortune to charity
Tunisia hotel attack: Locals form 'human shield' to protect hotel from gunman Seifeddine Rezgui
German ethics council calls for incest between siblings to be legalised by Government
Saudi Prince Alwaleed bin Talal will donate entire $32bn fortune to charity
Forget little green men - aliens will look like humans, says Cambridge University evolution expert
Greece debt crisis: Country on course to hold EU referendum as eurozone leaders reject new bailout request
The moment a Queen's Guard soldier lost it and drew his gun at annoying tourist
Greece crisis: IMF was pushed around by Angela Merkel and Nicholas Sarkozy – and now it is being humiliated
Greece crisis: The wider lesson is that it’s time to abandon this failed experiment in currencies
'I wish the BBC would stop calling it Islamic State' – David Cameron unleashes frustration at broadcaster
They are neither a 'state' nor 'Islamic': Why we shouldn't call them Isis, Isil or IS
Tunisia beach attack: How can British Muslims respond to the latest outrages?
iJobs Money & Business
£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...
£20000 - £25000 per annum + OTE £45K: SThree: SThree were established in 1986....
£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...
£22500 - £27000 per annum + OTE £45K: SThree: Since our inception in 1986, STh...